Venus bags first patent from Canada for antibiotic drug

Chandigarh based Venus Remedies Limited, a leading research based global pharmaceutical company has secured its first patent from Canada for its novel antibiotic adjuvant entity "Vancoplus". The patent has been granted by the Canadian patent office and is valid up to May 2027 and the company is planning to launch the product in Canada in the next two years.

Commenting on this accomplishment, Dr. (Mrs) Manu Chaudhary, JMD, Director- Research said, "We are really enthusiastic over the receival of this Canadian patent for VANCOPLUS, which will prove to be a fertile ground for the success of this product not just commercially but also in terms of catering to the constantly rising Methicillin Resistant Staphylococcus Aureus (MRSA) infection rates in Canada."

As per a research report published by Canadian Antimicrobial Resistance Alliance (CARA), the community acquired MRSA cases have increased significantly from 19.5% in 2007 to 38.1% in 2010. Discussing more about this patent Dr. Chaudhary further added, "At this time of need Vancoplus seems to be the only effective and safe option to curb the notorious MRSA strain.

The Company has already been marketing Vancoplus successfully in India and few of the merging markets across the globe. Venus Remedies' Baddi facility is already approved as per EU GMP for manufacturing of Vancoplus, which is in line with the Canadian Regulatory authorities to market the drug. Already Venus Remedies, headquartered in Panchkula, Haryana (India), is among the 10 leading fixed-dosage injectable manufacturers in the world. The company has three manufacturing units, in Panchkula, Baddi (both India) and Werne (Germany) and 11 overseas marketing offices including a presence in the US and Germany, she claimed.

ALSO READ

Air India to slash free baggage allowance, charge more

Kingfisher Airlines assets worth Rs 1,000 crore sold: SBI

Kansai Nerolac standalone Q4 net profit at Rs 122.7 cr

Adani Power loss soars to Rs 586 cr in Q4